Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
7
0
3

Year Published

2013
2013
2015
2015

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(10 citation statements)
references
References 14 publications
0
7
0
3
Order By: Relevance
“…A live-attenuated tetravalent vaccine that expresses the pre-membrane and envelope genes of each of the four DENV serotypes [62] within the 17D YFV vaccine has recently been tested in a clinical trial in healthy Thai children with an overall efficacy of ∼30% [63]. This poor finding was a result of very low efficacy against DENV 2, which was also the prevalent serotype during the study.…”
Section: Flavivirusesmentioning
confidence: 99%
“…A live-attenuated tetravalent vaccine that expresses the pre-membrane and envelope genes of each of the four DENV serotypes [62] within the 17D YFV vaccine has recently been tested in a clinical trial in healthy Thai children with an overall efficacy of ∼30% [63]. This poor finding was a result of very low efficacy against DENV 2, which was also the prevalent serotype during the study.…”
Section: Flavivirusesmentioning
confidence: 99%
“…A ChimeriVax (Sanofi Pasteur) -vacina atenuada tetravalente o que obsta à reinfeção por outros serotipos, baseada na produção da vacina da febre-amarela (17D) -em fase de estudo II, é a principal candidata neste momento. 53 O custo e eficácia de uma nova vacina não têm resposta no curto prazo -a acessibilidade deverá ser um problema nos países desfavorecidos, por sinal alguns dos mais afetados. Reforços nos meios de diagnóstico e a atualização dos profissionais de saúde são de interesse cada vez mais global, se atendermos ao fenómeno da dengue de importação.…”
Section: Medidas De Controlo: As Medidas De Controlo Dos Vetoresunclassified
“…CYD-TDV has undergone extensive safety and immunogenicity assessment in dengue endemic and non-endemic populations [10][11][12][13][14][15][16][17]. To fulfil the needs of phase III studies, the scale-up of CYD-TDV production has been undertaken in parallel with its clinical development [18]. Differences in the production of CYD-TDV lots used up to phase II and those used in phase III relate to the scale-up of the virus/cell culture.…”
Section: Introductionmentioning
confidence: 99%